DMRANasdaqPharmaceutical PreparationsUS GAAP · USD

Damora Therapeutics, Inc.

Damora Therapeutics, Inc. is a clinical-stage biotechnology company developing novel small-molecule therapeutics for cancer and liver diseases. The company is focused on product candidates GB1211 and GB3226, targeting areas with high unmet medical need and no disease-modifying treatment options.

Kysy yhtiöstä
Liikevoitto (EBIT)−211milj. USD
−847,3 %v/v
Nettotulos−210milj. USD
−878,8 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−250−200−150−100−50050milj. USD2020: EBIT 34 milj. USD20202021: EBIT −52 milj. USD20212022: EBIT −61 milj. USD20222023: EBIT −40 milj. USD20232024: EBIT −22 milj. USD20242025: EBIT −211 milj. USD2025−211
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
GB322650 %

Preclinical small-molecule program being advanced toward IND submission and later clinical development.

GB121135 %

Clinical-stage product candidate in the company's oncology and liver disease pipeline.

Discovery and pipeline expansion10 %

Research, in-licensing and development of additional product candidates and technologies.

Future commercialization5 %

Potential sales, marketing, medical affairs and distribution activities if candidates are approved.

Asiakkaat

Damora does not currently sell approved products; its near-term 'customers' are regulators, clinical trial participants, and contract research/manufacturing partners that enable development. If its programs succeed, the end-market customers would be patients with cancer or liver disease, along with physicians, hospitals and third-party payors that influence adoption and reimbursement.

Regulatory authorities

FDA, EMA and other agencies review preclinical and clinical data and determine whether programs can advance.

CRO and CMO partners

Contract research and manufacturing organizations provide trial execution, testing and drug supply.

Patients with oncology and liver disease

Future end users of approved therapies if GB1211, GB3226 or other candidates reach market.

Physicians and hospitals

Clinical decision-makers who would adopt the therapies based on efficacy, safety and convenience.

Third-party payors

Commercial and government payors that would determine access through coverage and reimbursement.

Strategia

The company is prioritizing GB3226 and GB1211, with GB3226 expected to advance through preclinical work and toward an IND filing. It is also seeking additional capital and potential collaborations to fund clinical development, while building the operational, regulatory and manufacturing capabilities needed for eventual commercialization.

Advance GB3226 to IND submissionLyhyt aikaväli

This is the clearest near-term value-creation milestone and supports progression into clinical development.

Fund the pipeline through additional capitalLyhyt aikaväli

The company expects substantial additional funding needs and has going-concern risk without financing.

Build development and commercialization infrastructureKeskipitkä aikaväli

Clinical-stage biotech requires regulatory, manufacturing and commercial capabilities before launch.

Protect intellectual property and secure partnershipsKeskipitkä aikaväli

Pipeline value depends on patent protection, exclusivity and access to external expertise and capital.

Maantiede

Damora is headquartered in the United States and its development work is centered on U.S. regulatory pathways, especially FDA interactions for GB3226. The company also references EMA and other foreign regulators, and it relies on international supply chains and third-party manufacturers, which creates exposure to trade policy and cross-border operating risk.

Riskit

Damora is a pre-revenue biotech with substantial going-concern and financing risk because it must fund long development cycles before any product revenue can emerge. Its business also depends on clinical success, regulatory approvals, IP protection and outsourced manufacturing, while trade restrictions and supply-chain disruptions can increase costs and delay programs.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Insufficient financing and going-concern risk1Clinical development and regulatory failure2Outsourced manufacturing and supply-chain disruption3Intellectual property and competition risk4Trade policy and geopolitical risk5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Insufficient financing and going-concern riskVaikutus: KriittinenTodennäköisyys: Kohtalainen

    The company states it will require substantial additional capital and may need to cut or stop programs if funding is unavailable.

    Kohdistuu: All development programs and corporate continuity

  2. Clinical development and regulatory failureVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Product candidates must succeed in preclinical and clinical studies and obtain FDA/other approvals before commercialization.

    KohdistuuGB3226GB1211Future pipeline assets
  3. Outsourced manufacturing and supply-chain disruptionVaikutus: KorkeaTodennäköisyys: Kohtalainen

    The company relies on third-party manufacturers and international inputs for preclinical and clinical supply.

    KohdistuuAPI supplyTrial materialsFuture scale-up
  4. Intellectual property and competition riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Value depends on maintaining patents, exclusivity and freedom to operate against competing therapies and third-party IP claims.

    Kohdistuu: Pipeline protection and future commercialization

  5. Trade policy and geopolitical riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Tariffs, import restrictions and geopolitical instability can raise costs and delay research or manufacturing activities.

    KohdistuuReagentsEquipmentOutsourced development

Kirjanpito

Harkinnanvaraiset erät
Research and development accruals

Management estimates costs for CROs, CMOs and other vendors before invoices arrive, affecting R&D expense and accrued liabilities.

Vaikutus: Can materially shift quarterly operating loss and working capital

Going-concern assessment

The company disclosed substantial doubt about its ability to continue as a going concern without additional financing.

Vaikutus: Important for liquidity analysis and capital structure risk

Deferred tax assets and valuation allowance

Loss carryforwards and temporary differences may not be realizable without future taxable income.

Vaikutus: Can affect tax benefit recognition and equity

Clinical trial cost timing

Study start-up, treatment and wrap-up periods create uneven expense recognition across quarters.

Vaikutus: Reduces comparability of period-to-period R&D spend

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Tyra Biosciences, Inc.

TYRA · Pharmaceutical Preparations

Kymera Therapeutics, Inc.

KYMR · Biological Products, (No Diagnostic Substances)

Relay Therapeutics, Inc.

RLAY · Biological Products, (No Diagnostic Substances)

Bicara Therapeutics Inc.

BCAX · Pharmaceutical Preparations

Larimar Therapeutics, Inc.

LRMR · Pharmaceutical Preparations

Marker Therapeutics, Inc.

MRKR · Pharmaceutical Preparations

Päivitetty: 24.9.2026

Damora Therapeutics, Inc. (Nasdaq) – Pharmaceutical Preparations | Analyysi – Clarifo